EE508 Cost of Liver Cancer Screening in Patients with Cirrhosis

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest growing cause of cancer deaths among Americans. Guidelines recommend biannual ultrasound-based screening, with or without a serum biomarker alpha fetoprotein (AFP) for early detection of HCC in at-risk individuals with cirrhosis. Our objective was to estimate the overall cost of HCC screening from a commercial healthcare system’s perspective.